Cholesterol Efflux Capacity and Pre-Beta-1 HDL Concentrations Are Increased in Dyslipidemic Patients Treated With Evacetrapib

This publication has 32 references indexed in Scilit:

• Paradoxical Association of Enhanced Cholesterol Efflux With Increased Incident Cardiovascular Risks
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2013
• Effects of Dalcetrapib in Patients with a Recent Acute Coronary Syndrome
  New England Journal of Medicine, 2012
• Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study
  The Lancet, 2012
• Effects of the CETP Inhibitor Evacetrapib Administered as Monotherapy or in Combination With Statins on HDL and LDL Cholesterol
  JAMA, 2011
• Cholesterol Efflux Capacity, High-Density Lipoprotein Function, and Atherosclerosis
  New England Journal of Medicine, 2011
• Cholesterol Efflux Potential and Antiinflammatory Properties of High-Density Lipoprotein After Treatment With Niacin or Anacetrapib
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2010
• The Ability to Promote Efflux Via ABCA1 Determines the Capacity of Serum Specimens With Similar High-Density Lipoprotein Cholesterol to Remove Cholesterol From Macrophages
  Arteriosclerosis, Thrombosis, and Vascular Biology, 2010
• Major Lipids, Apolipoproteins, and Risk of Vascular Disease
  JAMA, 2009
• Beyond High-Density Lipoprotein Cholesterol Levels
  JACC, 2008
• Two-dimensional electrophoresis of plasma lipoproteins: Recognition of new apo A-I-containing subpopulations
  Biochimica et Biophysica Acta (BBA) - Lipids and Lipid Metabolism, 1993